IL-12-话题@MedSci

#IL-12#

28篇内容 | 727人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1978168, encodeId=868119e816838, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, objectType=article, longId=725659, objectId=d704e2565909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d704e2565909, replyNumber=0, likeNumber=40, createdTime=2022-05-30, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d704e2565909, moduleTitle=托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d704e2565909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978170, encodeId=557a19e8170b4, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, objectType=article, longId=736657, objectId=c691e366579d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c691e366579d, replyNumber=0, likeNumber=44, createdTime=2023-04-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c691e366579d, moduleTitle=Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c691e366579d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978166, encodeId=fbd919e816615, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标, objectType=article, longId=293933, objectId=3de72939337a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3de72939337a, replyNumber=0, likeNumber=38, createdTime=2022-09-23, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3de72939337a, moduleTitle=Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3de72939337a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978169, encodeId=f7bd19e8169b4, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, objectType=article, longId=730741, objectId=13a2e30741f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a2e30741f5, replyNumber=0, likeNumber=40, createdTime=2023-05-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a2e30741f5, moduleTitle=ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a2e30741f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978167, encodeId=112619e81675d, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低, objectType=article, longId=294243, objectId=b57629424374, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b57629424374, replyNumber=0, likeNumber=37, createdTime=2022-11-20, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b57629424374, moduleTitle=Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b57629424374)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978165, encodeId=37bd19e816565, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物, objectType=article, longId=293651, objectId=d6b329365133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d6b329365133, replyNumber=0, likeNumber=26, createdTime=2022-02-11, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d6b329365133, moduleTitle=Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d6b329365133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978164, encodeId=284d19e816436, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=ARD：抑制IL-12/23（优特克单抗）与肿瘤坏死因子在银屑病关节炎中的有效性, objectType=article, longId=219933, objectId=b0dc21993361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0dc21993361, replyNumber=0, likeNumber=41, createdTime=2022-09-18, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0dc21993361, moduleTitle=ARD：抑制IL-12/23（优特克单抗）与肿瘤坏死因子在银屑病关节炎中的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0dc21993361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978163, encodeId=71ea19e816368, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=BMC: 肠粘膜中IL-12表达增加与溃疡性结肠炎的复发有关, objectType=article, longId=208945, objectId=86172089459d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=86172089459d, replyNumber=0, likeNumber=29, createdTime=2021-07-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=86172089459d, moduleTitle=BMC: 肠粘膜中IL-12表达增加与溃疡性结肠炎的复发有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=86172089459d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978162, encodeId=20fd19e8162aa, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎, objectType=article, longId=203361, objectId=d59f203361c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d59f203361c6, replyNumber=0, likeNumber=27, createdTime=2021-06-10, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d59f203361c6, moduleTitle=Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d59f203361c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978156, encodeId=3f5019e815686, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=46, createdTime=2020-07-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978161, encodeId=7cf119e81612d, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！, objectType=article, longId=199213, objectId=bdd519921302, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdd519921302, replyNumber=0, likeNumber=18, createdTime=2021-06-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdd519921302, moduleTitle=期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdd519921302)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978159, encodeId=ce2219e8159eb, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, objectType=article, longId=196588, objectId=da7919658856, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da7919658856, replyNumber=0, likeNumber=27, createdTime=2020-06-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da7919658856, moduleTitle=由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da7919658856)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978160, encodeId=f48919e8160f4, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=44, createdTime=2021-02-19, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978154, encodeId=94e319e8154b5, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, objectType=article, longId=187183, objectId=a1b618e18333, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1b618e18333, replyNumber=0, likeNumber=30, createdTime=2020-11-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1b618e18333, moduleTitle=被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1b618e18333)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978157, encodeId=56b819e815748, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=36, createdTime=2021-05-29, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978158, encodeId=5a5b19e8158b9, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, objectType=article, longId=196065, objectId=c775196065fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c775196065fc, replyNumber=0, likeNumber=40, createdTime=2021-05-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c775196065fc, moduleTitle=英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c775196065fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978155, encodeId=d51419e815504, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, objectType=article, longId=188168, objectId=b557188168d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b557188168d1, replyNumber=0, likeNumber=40, createdTime=2020-10-17, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b557188168d1, moduleTitle=Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b557188168d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978151, encodeId=e54219e815175, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效, objectType=article, longId=178017, objectId=010a1e801749, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=010a1e801749, replyNumber=0, likeNumber=39, createdTime=2020-07-16, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=010a1e801749, moduleTitle=Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=010a1e801749)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978152, encodeId=243f19e81526c, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=38, createdTime=2020-02-02, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1978153, encodeId=0fef19e815312, content=<a href='/topic/show?id=ef8e962eb5' target=_blank style='color:#2F92EE;'>#IL-12#</a>, objectTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, objectType=article, longId=183565, objectId=c2ab183565aa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ab183565aa, replyNumber=0, likeNumber=31, createdTime=2020-01-09, rootId=0, userName=仁者大医, userId=8e886, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ab183565aa, moduleTitle=2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ab183565aa)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-12

2020-05-29

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

托法替尼对银屑病患者皮肤和血液中IL-12/IL-23 p40亚单位的抑制依赖于树突状细胞中活性干扰素-γ信号传导研究

2022-05-30

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Am J Clin Dermatol：IL-12/23、IL-17和IL-23抑制剂治疗银屑病的药物存活率

2023-04-18

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Cardiovasc Diabetol：IL-12/23p40水平升高可作为2型糖尿病心率变异性功能障碍的潜在指标

2022-09-23

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

ARD：IL-12/23通路抑制剂优特克单抗或TNFi 治疗银屑病关节炎患者的持久性和有效性相当

2023-05-17

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Nat Biomed Eng：给免疫系统踩油门，MIT开发IL-12+明矾疗法，高效杀伤肿瘤，且副作用更低

2022-11-20

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Science Immunology：彭华/傅阳心合作开发新一代高效低毒肿瘤特异性IL-12前体药物

2022-02-11

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

ARD：抑制IL-12/23（优特克单抗）与肿瘤坏死因子在银屑病关节炎中的有效性

2022-09-18

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

BMC: 肠粘膜中IL-12表达增加与溃疡性结肠炎的复发有关

2021-07-17

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Clin Exp Hypertens：阻断IL-12和/或IL-23可改善主动脉血管炎

2021-06-10

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2020-07-16

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

期刊速递丨肿瘤治疗新公式？多功能溶瘤纳米颗粒+可自我复制的IL-12 RNA=消灭肿瘤！

2021-06-17

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

由于缺乏疗效，强生放弃IL-12/IL-23单抗Stelara治疗系统性红斑狼疮的三期研究

2020-06-29

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2021-02-19

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

被英国NICE拒绝后，强生的IL-23/IL-12单抗Stelara获得欧盟扩展适应症治疗儿童牛皮癣

2020-11-02

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2021-05-29

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

英国NICE首次批准靶向IL-12/IL-23的单抗Stelara，用于治疗溃疡性结肠炎

2021-05-16

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Janssen宣布其IL-12/IL-23单抗Stelara治疗克罗恩病的III期中期分析阳性结果

2020-10-17

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

Sci transl med：IL-12基因疗法治疗复发性高级别胶质瘤的安全性和疗效

2020-07-16

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2020-02-02

仁者大医 (审核中...)

前往app查看评论内容

#IL-12#

2019年神经肿瘤学会：IL-12治疗复发性胶质母细胞瘤的临床数据

2020-01-09

科室
- - 订阅+
  - 更多科室
工具
服务